alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 65, Number 227 (Friday, November 24, 2000)]
[Notices]
[Page 70549]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-30039]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

International Trade Administration

[A-570-836]


Notice of Postponement of Final Results of Antidumping Duty New 
Shipper Review: Glycine from the People's Republic of China

AGENCY: Import Administration, International Trade Administration, 
Department of Commerce.

ACTION: Notice of postponement of final results of antidumping duty new 
shipper review.

-----------------------------------------------------------------------

EFFECTIVE DATE: November 24, 2000.

FOR FURTHER INFORMATION CONTACT: Robert Bolling or Rick Johnson, Office 
IX, DAS Group III, Import Administration, International Trade 
Administration, U.S. Department of Commerce, 14th Street and 
Constitution Avenue NW, Washington, DC 20230; telephone (202) 482-3434 
and (202) 482-3818, respectively.

POSTPONEMENT OF FINAL RESULTS: The Department of Commerce (``the 
Department'') is postponing the final results in the antidumping duty 
new shipper review of glycine from the People's Republic of China. The 
deadline for issuing the final results in this new shipper review is 
now January 24, 2001.
    On November 15, 1999, the Department initiated this new shipper 
administrative review. See Initiation of New Shipper Administrative 
Review, 64 FR 61834 (November 15, 1999). The date for issuing the final 
results of the review was November 25, 2000. In order to provide 
interested parties an opportunity to comment on the issue of whether 
glycine and phenylglycine are comparable products, which arose late in 
the proceeding, we are extending the time limit for the final results 
of the new shipper administrative review of glycine from the People's 
Republic of China by 60 days, in accordance with section 751(a)(3) of 
the Tariff Act of 1930, as amended. See November 16, 2000 memorandum 
from Edward Yang to Joseph Spetrini: Extension of Time Limit for the 
New Shipper Administrative Review of Glycine from the People's Republic 
of China. The date for issuing the final results is now January 24, 
2001.

    Dated: November 16, 2000.
Joseph A. Spetrini,
Deputy Assistant Secretary, AD/CVD Enforcement Group III.
[FR Doc. 00-30039 Filed 11-22-00; 8:45 am]
BILLING CODE 3510-DS-P
Exhibit 32.2





CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Annual Report of Venture Lending & Leasing VIII, Inc. (the "Fund") on Form 10-K for the year ending December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Martin D. Eng, Chief Financial Officer of the Fund, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:


(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Fund.





/S/ Martin D. Eng





Martin D. Eng


Chief Financial Officer


March 15, 2016
**The Whistleblower Protection Enhancement Act of 2012 ("WPEA"), Pub.L. 112-199**

As a Department manager, supervisor, or official, you must not use your authority to take, threaten to take, or fail to take a personnel action against an employee or applicant because that individual makes a disclosure of information under the Whistleblower Protection Act, as amended, that the individual reasonably believes shows:

·  Violation of law, rule, regulation

·  Gross Mismanagement

·  Gross Waste of Funds

·  Abuse of Authority

·  Substantial and Specific Danger to the Public Health or Safety

If an individual makes a disclosure protected by the Whistleblower Protection Act, management cannot take a retaliatory personnel action against the whistleblower. Personnel actions covered by the Whistleblower Protection Act include:

·  An appointment or promotion

·  A disciplinary, adverse, or corrective action

·  A detail, transfer, or reassignment

·  A reinstatement, restoration, or reemployment

·  A decision about pay, benefits, awards, or training

·  A performance evaluation

·  A significant change in duties, responsibilities, or working conditions

· The enforcement of non-disclosure agreements that fail to inform employees that any such agreement does not supersede their whistleblower rights.

It is also unlawful to retaliate against a person who engages in protected activity.  Protected activity includes filing a Whistleblower grievance with the agency, filing a complaint with an agency’s Office of Inspector General (OIG) or the Office of Special Counsel (OSC), and filing a Whistleblower appeal with the Merit Systems Protection Board (MSPB).  Protected activity also includes participation in or cooperation with an investigation or inquiry conducted by the OSC or the agency’s OIG, and refusing to obey an order that would require the individual to violate a law.

The Whistleblower Protection Act does not cover disclosures that are **specifically prohibited by law** or if the information is required under Executive Order to be protected from disclosure in the interest of national security, unless that disclosure is made to the OSC or OIG.

The provisions of the Whistleblower Protection Act supersede non-disclosure agreements between an employee and the agency.

You may file a Whistleblower Protection Act complaint by contacting the:

Office of Special Counsel

Disclosure Unit

1730 M Street, Northwest

Suite 218

Washington, DC 20036

Or by calling 1-800-572-2249 or 202-254-3640

You may also obtain additional information or file a complaint online at:

www.osc.gov
Federal Advisory Committee on Insurance

Agenda

December 2, 2021

12:30 – 12:45 pm Introduction & FIO Update

12:45 – 1:15 pm Presentation and Discussion on Climate-Related Financial 

Risk and the Insurance Sector by FIO Staff

1:15 – 1:45 pm Discussion Led by the Protection Gap Subcommittee

1:45 – 2:00 pm Update from the Subcommittee on FIO’s International Work 

2:00 – 2:05 pm New Business

2:05 pm Adjourn
**Exhibit 32.2**

 

CERTIFICATIONPURSUANT TO

 

18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO

SECTION 906OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of SureWestCommunications (the “Company”), on Form 10-Q for the period ended March 31,2008 as filed with the Securities and Exchange Commission of the date hereof(the “Report”), the undersigned, as the Chief Financial Officer of the Company,hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuantto Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

1.                  The Report fully complies with the requirements of Section 13(a) orSection 15(d) of the Securities Exchange Act of 1934; and

 

2.                  The information contained in the Report fairlypresents, in all material respects, the financial condition and results ofoperations of the Company.

 
| Date: May 5, 2008 | By:    | /s/ Dan T. Bessey       |
|------------------------|--------|-------------------------|
|                   |   | Dan T. Bessey,          |
|                   |   | Vice President and      |
|                   |   | Chief Financial Officer |

 

A signed original of this written statement requiredby Section 906 has been provided to SureWest Communications and will beretained by SureWest Communications and furnished to the Securities andExchange Commission or its staff upon request.

 

The foregoing certificate is being furnished to theSecurities and Exchange Commission as an exhibit to the Form 10-Q andshall not be considered filed as part of the Form 10-Q.

 

----
IN THE UNITED STATES DISTRICT COURT

FOR THE NORTHERN DISTRICT OF TEXAS

AMARILLO DIVISION

UNITED STATES OF AMERICA §

§

v. § 2:22-CR-00109-Z-BR

§

EFREN HERNANDEZ-AGUILAR (1) §

REPORT AND RECOMMENDATION

CONCERNING PLEA OF GUILTY

EFREN HERNANDEZ-AGUILAR (1), by consent, under authority of United States v. Dees, 125 F.3d 261 (5th 

Cir. 1997), has appeared before me pursuant to FED. R. CRIM. P. 11, and has entered a plea of guilty to Count 1 of the 

Indictment. After cautioning and examining EFREN HERNANDEZ-AGUILAR (1) under oath concerning each of the 

subjects mentioned in Rule 11, I determined that the guilty plea was knowledgeable and voluntary and that the offense 

charged is supported by an independent basis in fact containing each of the essential elements of such offense. I therefore 

recommend that the plea of guilty be accepted, and that EFREN HERNANDEZ-AGUILAR (1) be adjudged guilty of 8 

U.S.C. §§ 1326(a) and (b)(1); and 6 U.S.C. §§ 202(3), 202(4), and 557 - ILLEGAL RE-ENTRY AFTER DEPORTATION

and have sentence imposed accordingly. After being found guilty of the offense by the District Judge,

☒ The defendant is currently in custody and should be ordered to remain in custody.

☐ The defendant must be ordered detained pursuant to 18 U.S.C. § 3143(a)(1) unless the Court finds by clear and 

convincing evidence that the defendant is not likely to flee or pose a danger to any other person or the community 

if released.

☐ The Government does not oppose release.

☐ The defendant has been compliant with the current conditions of release.

☐ I find by clear and convincing evidence that the defendant is not likely to flee or pose a danger to any other 

person or the community if released and should therefore be released under § 3142(b) or (c).

☐ The Government opposes release.

☐ The defendant has not been compliant with the conditions of release.

☐ If the Court accepts this recommendation, this matter should be set for hearing upon motion of the 

Government.

☐ The defendant must be ordered detained pursuant to 18 U.S.C. § 3143(a)(2) unless (1)(a) the Court finds there is a 

substantial likelihood that a motion for acquittal or new trial will be granted, or (b) the Government has 

recommended that no sentence of imprisonment be imposed, or (c) exceptional circumstances are clearly shown 

under § 3145(c) why the defendant should not be detained, and (2) the Court finds by clear and convincing evidence 

that the defendant is not likely to flee or pose a danger to any other person or the community if released.

Date: December 14, 2022

______________________________________

UNITED STATES MAGISTRATE JUDGE

NOTICE

Failure to file written objections to this Report and Recommendation within fourteen (14) days from the date of its 

service shall bar an aggrieved party from attacking such Report and Recommendation before the assigned United States 

District Judge. 28 U.S.C. § 636(b)(1)(B).

Case 2:22-cr-00109-Z-BR Document 27 Filed 12/14/22 Page 1 of 1 PageID 50
Exhibit 10.1


 


 






    

     

    

 





N66001-11-C-4188


P00012


Page 2 of 3


 


SECTION SF 30 BLOCK 14 CONTINUATION PAGE 


 


SUMMARY
OF CHANGES


 


SECTION A - SOLICITATION/CONTRACT FORM


 


The total cost of this contract was increased
by $581,157.00 from $5,354,839.00 to $5,935,996.00.


 


SECTION B - SUPPLIES OR SERVICES AND PRICES


 


CLIN 0011


The option status has changed from
        Option to Option Exercised.


 


CLIN 0012


The option status has changed from
        Option to Option Exercised.


 


SUBCLIN 001101 is added as follows:


 


	001101	Funding for Opt 4 MIPR#	ACRN 	$581,157.00
	 	 HR0011518340 	AH 	 



 


 


SECTION E - INSPECTION AND ACCEPTANCE


 


The following Acceptance/Inspection Schedule was added for
SUBCLIN 001101:





	INSPECT AT	INSPECT BY 	ACCEPT AT	ACCEPT BY
	N/A	N/A	N/A	Government




 


 


 


SECTION G - CONTRACT ADMINISTRATION DATA


 


Accounting
and Appropriation


 


Summary for the Payment Office


 


As a result
of this modification, the total funded amount for this document was increased by $581,157.00 from $5,354,839.00 to $5,935,996.00.


 


SUBCLIN 001101:


Funding on SUBCLIN 001101 is initiated as follows:


 


ACRN: AH


 


CIN: 130021178700011


 






    

     

    

 


N66001-11-C-4188


P00012


Page
3  of 3


 



Acctng
Data: 9715160400 1320 BDL TTT20 1 5BT01C OR EADARP A255HR001151 83400200020602115E00 012199


 


Increase: $581,157.00


 


Total: $581,157.00


 


(End of Summary of Changes)
**Exhibit 32.2**

 

CERTIFICATION PURSUANT TO 18 U.S.C.SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

 

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002(subsections (a) and (b) of section 1350, chapter 63 of Title 18, UnitedStates Code), the undersigned officer of NeoPharm, Inc., a Delaware corporation(the “Company”), does hereby certify with respect to the Quarterly Report ofthe Company on Form 10-Q for the quarter ended June 30, 2005 as filed withthe Securities and Exchange Commission (the “10-Q Report”) that:

 

(1)                                  the 10-Q Report fullycomplies with the requirements of section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and

 

(2)                                  the informationcontained in the 10-Q Report fairly presents, in all material respects, thefinancial condition and results of operations of the Company.

 

 
| Dated:  August 9, 2005 | /s/ Lawrence A. Kenyon  |   |
|-----------------------------|-------------------------|--------|
|                        | Lawrence A. Kenyon,     |
|                        | Chief Financial Officer |

 

----

Thiscertification shall not be deemed filed for purposes of Section 18 of theSecurities Exchange Act of 1934, or otherwise subject to the liability of thatsection, nor shall it be deemed to be incorporated by reference into any filingunder the Securities Act of 1933 or the Securities Exchange Act of 1934.

 

----
[Federal Register Volume 65, Number 229 (Tuesday, November 28, 2000)]
[Notices]
[Page 70898]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-30209]



[[Page 70898]]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RM98-1-000]


Regulations Governing Off-the-Record Communications; Public 
Notice

November 21, 2000.
    This constitutes notice, in accordance with 18 CFR 385.220(h), of 
the receipt of exempt and prohibited off-the-record communications.
    The following is a list of exempt and prohibited off-the-record 
communications received in the Office of the Secretary within the 
preceding 14 days.
    None were received.

David P. Boergers,
Secretary.
[FR Doc. 00-30209 Filed 11-27-00; 8:45 am]
BILLING CODE 6717-01-M
Exhibit 10.1


 





		
        2345 Eastlake Ave E, Suite 201

        Seattle, WA 98102

        Office: 800-351-3902

        Fax: 206-430-1288

        www.atossagenetics.com



 


September 1, 2015


 


Scott Youmans


[******]


[******]


 


*Hand Delivered


 


Dear Scott,


 


A significant factor in our success at Atossa Genetics
is our people and the effort and talent they bring to the workplace. In recognition of this importance, we are pleased to
inform you that you will be promoted from Sr. Vice President, Operations to Chief Operating Officer, effective September 1,
2015. This is a Section 16 Officer position and the annual rate of pay will be $287,040. In addition, you will be granted an
option to purchase  50,000 shares of Atossa Genetics common stock at the closing price on the date approved by the board,
which vests over four years of employment with no cliff. 


 


In your time with Atossa, you have quickly
demonstrated your work ethic, dedication, and your superb qualifications. We have faith that you will continue to excel in
your new position and hope that you continue to develop your potential here at Atossa Genetics. 


 


Congratulations on this promotion, and we look forward to
your contributions in your new position.


 


Thank you for being such a valuable asset to Atossa
Genetics and for your loyal service.


 


Sincerely,





/s/ Steven C. Quay, MD, PHD, FCAP


Steven C. Quay, MD, PHD, FCAP


CEO and President


 





	/s/ Scott Youmans	 	09/01/2015
	Acknowledgement of receipt – Scott Youmans	 	Date
|   | 1. | The Quarterly Report on Form 10-Q      of the Company for the quarter ended September 30, 2010 (the "Report")      fully complies with the requirements of Section 13(a) or 15(d) of the      Securities Exchange Act of 1934 (U.S.C. 78m or 78o(d));      and |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | The information contained in the      Report fairly presents, in all material respects, the financial condition      and results of operations of theCompany. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  Date:  November      12, 2010 |   | /s/ Edward Yihua  Kang        |
|-----------------------------------------------|--------|------------------------------------|
|                                          |   | Edward      Yihua Kang             |
|                                          |   | Chief      Executive Officer       |
|                                          |   | (Principal      Executive Officer) |

----
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 00-1651

BETTY J. JACKSON,

Plaintiff - Appellant,

versus

MECKLENBURG COUNTY; LAVONNE D. JACKSON; BILLY

F. JACKSON,

Defendants - Appellees.

Appeal from the United States District Court for the Western District of North Carolina, at Charlotte. Graham C. Mullen, Chief

District Judge. (CA-99-517-3-MU)

Submitted: September 8, 2000 Decided: September 15, 2000

Before LUTTIG and KING, Circuit Judges, and HAMILTON, Senior Circuit Judge.

Affirmed by unpublished per curiam opinion.

Betty J. Jackson, Appellant Pro Se. James Orr Cobb, Jr., RUFF,

BOND, COBB, WADE & MCNAIR, Charlotte, North Carolina; Lavonne D.

Jackson; Billy F. Jackson, Charlotte, North Carolina, for

Appellees.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
* Although the district court’s order is marked as “filed” on

May 3, 2000, the district court’s records show that it was entered

on the docket sheet on May 9, 2000. Pursuant to Rules 58 and 79(a)

of the Federal Rules of Civil Procedure, it is the date that the

order was physically entered on the docket sheet that we take as

the effective date of the district court’s decision. See Wilson v.

Murray, 806 F.2d 1232, 1234-35 (4th Cir. 1986).

2

PER CURIAM:

Betty J. Jackson appeals the district court’s order dismissing

her action alleging employment discrimination. We have reviewed

the record and the district court’s opinion and find no reversible

error. Accordingly, we affirm on the reasoning of the district

court. See Jackson v. Mecklenburg County, No. CA-99-517-3-MU

(W.D.N.C. May 9, 2000).* We dispense with oral argument because

the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional

process.

AFFIRMED
Dolan Chemical Laboratory 4001 Bixby Road Groveport, OH 43125 T: 614-836-4221, Audinet 210-4221 F: 614-836-4168, Audinet 210-4168 http://aepenv/labs 

### Water Analysis
Location: Mountaineer Plant Report Date: 7/17/2012 Form REP-702 Rev. 0, 4/2012



### Sample Number: 122994-001 Date Collected: 07/10/2012 14:10 Date Received:7/11/2012 

### 1st Stage Feed Units Parameter Result RL Analysis By Analysis Date/Time Method MDL ug/L Selenium, Se 438 0.5 DPC EPA 200.8 0.1 07/16/2012 15:21 

### Sample Number: 122994-002 Date Collected:07/10/2012 14:10 Date Received:7/11/2012 

## 2nd Stage Feed Units Parameter Result RL Analysis By Analysis Date/Time Method MDL ug/L Selenium, Se 28.7 0.5 DPC EPA 200.8 0.1 07/16/2012 15:25 

### Sample Number: 122994-003 Date Collected:07/10/2012 14:10 Date Received:7/11/2012 

### Bioreactor Effluent Units Parameter Result RL Analysis By Analysis Date/Time Method MDL ug/L Selenium, Se 1.0 0.5 DPC EPA 200.8 0.1 07/16/2012 15:30

THIS TEST REPORT RELATES ONLY TO THE ITEMS TESTED AND SHALL NOT BE REPRODUCED EXCEPT IN FULL WITHOUT WRITTEN APPROVAL OF THE LABORATORY. ALL TEST RESULTS MEET ALL OF THE REQUIREMENTS OF THE ACCREDITING AUTHORITY, UNLESS OTHERWISE NOTED.

Brian Snyder, Chemist II Email bssnyder@aep.com Tel. 614-836-4224 Fax 614-836-4168 Audinet 210-4224

Mountaineer Plant, 122994 Page 1 of 1
Case 3:22-cv-02538-S-BN Document 21 Filed 04/04/23 Page 1 of 10 PageID 179
Case 3:22-cv-02538-S-BN Document 21 Filed 04/04/23 Page 2 of 10 PageID 180
Case 3:22-cv-02538-S-BN Document 21 Filed 04/04/23 Page 3 of 10 PageID 181
Case 3:22-cv-02538-S-BN Document 21 Filed 04/04/23 Page 4 of 10 PageID 182
Case 3:22-cv-02538-S-BN Document 21 Filed 04/04/23 Page 5 of 10 PageID 183
Case 3:22-cv-02538-S-BN Document 21 Filed 04/04/23 Page 6 of 10 PageID 184
Case 3:22-cv-02538-S-BN Document 21 Filed 04/04/23 Page 7 of 10 PageID 185
Case 3:22-cv-02538-S-BN Document 21 Filed 04/04/23 Page 8 of 10 PageID 186
Case 3:22-cv-02538-S-BN Document 21 Filed 04/04/23 Page 9 of 10 PageID 187
Case 3:22-cv-02538-S-BN Document 21 Filed 04/04/23 Page 10 of 10 PageID 188
US Oncology, Inc



Exhibit 32.1



CERTIFICATION PURSUANT TO

18 U.S.C.
SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of US Oncology, Inc. (the Company) on Form 10-Q for the period ending June 30, 2004 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, R.
Dale Ross, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



|(1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|--- | ---------------------------------------------------------------------------------------------------------------------



|(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------



|                                            
|--------------------------------------------
|/s/ R. Dale Ross                            
|R. Dale Ross                                
|Chief Executive Officer of US Oncology, Inc.
|                                            
|July 23, 2004